![[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!](https://businessfortnight.com/wp-content/uploads/2025/10/Toyota-Times-Century-as-a-Brand-Lexus-as-Innovation-All-218x150.jpg "[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!")
EMERYVILLE, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics firm harnessing the ability of directed evolution for focused genetic medicines, introduced that administration will take part in the next upcoming investor conferences:
| Event: Jefferies Cell and Genetic Medicine Summit Format: Corporate Presentation Date & Time: Friday, September 30, 2022, at 9:00 a.m. ET |
|
| Event: Chardan’s 6th Annual Genetic Medicines Conference Format: 1×1 Meetings Date & Time: Monday, October 3, 2022 |
A reside audio webcast of the presentation can be accessible by visiting the “Investors & Media” part of the 4DMT web site at www.4dmoleculartherapeutics.com. A replay of the webcast can be accessible for at the least two weeks following the reside occasion.
About 4DMT
4DMT is a clinical-stage biotherapeutics firm harnessing the ability of directed evolution for focused genetic medicines. 4DMT seeks to unlock the complete potential of genetic medicines utilizing its platform, Therapeutic Vector Evolution, which mixes the ability of directed evolution with roughly one billion artificial capsid sequences to invent focused and developed vectors to be used in our merchandise. The firm is initially targeted on 5 clinical-stage merchandise in three therapeutic areas for each uncommon and huge market ailments: ophthalmology, cardiology (together with Fabry illness) and pulmonology. The 4DMT focused and developed vectors are invented with the objective of being delivered at comparatively low doses via clinically routine, nicely tolerated and minimally invasive routes of administration, transducing diseased cells in goal tissues effectively, having diminished immunogenicity and, the place related, having resistance to pre-existing antibodies. The 5 4DMT product candidates in medical growth are: 4D-150 for moist AMD, 4D-310 for Fabry illness, 4D-710 for cystic fibrosis, 4D-125 for XLRP, and 4D-110 for choroideremia.
4D-150, 4D-310, 4D-710, 4D-125, and 4D-110 are in medical trials and haven’t but been permitted for advertising and marketing by the US FDA or every other regulatory authority. No illustration is made as to the protection or effectiveness of 4D-150, 4D-310, 4D-710, 4D-125, and 4D-110 for the therapeutic use for which they’re being studied. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT emblem are emblems of 4DMT.
Contacts:
Media:
Katherine Smith
Evoke Canale
[email protected]
Investors:
Mike Zanoni
VP, Investor Relations
[email protected]
